| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.36.1.64 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC189227 |
| https://europepmc.org/articles/PMC189227?pdf=render | ||
| P932 | PMC publication ID | 189227 |
| P698 | PubMed publication ID | 1590702 |
| P2093 | author name string | Yarosh-Tomaine T | |
| G. H. Miller | |||
| R. S. Hare | |||
| B. Antonacci | |||
| D. Loebenberg | |||
| Moss EL Jr | |||
| F. Menzel | |||
| E. L. Moss | |||
| C. Norris | |||
| A. Cacciapuoti | |||
| Menzel F Jr | |||
| R. Parmegiani | |||
| T. Yarosh-Tomaine | |||
| P2860 | cites work | SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits | Q28331634 |
| Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes | Q28360287 | ||
| In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum | Q35251766 | ||
| Treatment of murine coccidioidal meningitis with SCH39304 | Q35252722 | ||
| Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis | Q35256048 | ||
| In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent | Q35257842 | ||
| Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts | Q35269220 | ||
| Efficacy of SCH39304 in murine cryptococcosis | Q35342439 | ||
| Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients | Q35535361 | ||
| Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice | Q35648045 | ||
| Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent | Q39815975 | ||
| Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. | Q39820104 | ||
| In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy | Q39833078 | ||
| In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole | Q68760517 | ||
| Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes | Q68933500 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluconazole | Q411478 |
| P304 | page(s) | 64-67 | |
| P577 | publication date | 1992-01-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice | |
| P478 | volume | 36 |
| Q41740968 | Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development |
| Q40932334 | Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients |
| Q35826590 | In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304 |
| Q28344464 | In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida |
| Q33803508 | Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo |
| Q29617839 | Nonfilamentous C. albicans mutants are avirulent |
| Q33980421 | Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis |
| Q33982075 | Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo |
Search more.